These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 24390212)

  • 1. Cost of poor adherence to anti-hypertensive therapy in five European countries.
    Mennini FS; Marcellusi A; von der Schulenburg JM; Gray A; Levy P; Sciattella P; Soro M; Staffiero G; Zeidler J; Maggioni A; Schmieder RE
    Eur J Health Econ; 2015 Jan; 16(1):65-72. PubMed ID: 24390212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy.
    Wille E; Scholze J; Alegria E; Ferri C; Langham S; Stevens W; Jeffries D; Uhl-Hochgraeber K
    Eur J Health Econ; 2011 Jun; 12(3):205-18. PubMed ID: 20405160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe.
    Hansson L; Lloyd A; Anderson P; Kopp Z
    Blood Press; 2002; 11(1):35-45. PubMed ID: 11926349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease.
    Lamotte M; Annemans L; Evers T; Kubin M
    Pharmacoeconomics; 2006; 24(2):155-69. PubMed ID: 16460136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost of disorders of the brain in Europe 2010.
    Gustavsson A; Svensson M; Jacobi F; Allgulander C; Alonso J; Beghi E; Dodel R; Ekman M; Faravelli C; Fratiglioni L; Gannon B; Jones DH; Jennum P; Jordanova A; Jönsson L; Karampampa K; Knapp M; Kobelt G; Kurth T; Lieb R; Linde M; Ljungcrantz C; Maercker A; Melin B; Moscarelli M; Musayev A; Norwood F; Preisig M; Pugliatti M; Rehm J; Salvador-Carulla L; Schlehofer B; Simon R; Steinhausen HC; Stovner LJ; Vallat JM; Van den Bergh P; van Os J; Vos P; Xu W; Wittchen HU; Jönsson B; Olesen J;
    Eur Neuropsychopharmacol; 2011 Oct; 21(10):718-79. PubMed ID: 21924589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
    Schwander B; Gradl B; Zöllner Y; Lindgren P; Diener HC; Lüders S; Schrader J; Villar FA; Greiner W; Jönsson B
    Value Health; 2009 Sep; 12(6):857-71. PubMed ID: 19508663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
    Tunis SL; Willis WD; Foos V
    Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simulating the impact of improved cardiovascular risk interventions on clinical and economic outcomes in Russia.
    Shum K; Alperin P; Shalnova S; Boytsov S; Kontsevaya A; Vigdorchik A; Guetz A; Eriksson J; Hughes D
    PLoS One; 2014; 9(8):e103280. PubMed ID: 25141122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimated annual direct expenditures in the United States as a result of inappropriate hypertension treatment according to national treatment guidelines.
    Balu S
    Clin Ther; 2009 Jul; 31(7):1581-94. PubMed ID: 19695408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular disease costs associated with uncontrolled hypertension.
    Flack JM; Casciano R; Casciano J; Doyle J; Arikian S; Tang S; Arocho R
    Manag Care Interface; 2002 Nov; 15(11):28-36. PubMed ID: 12449899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK.
    Lafuma A; Brézin A; Lopatriello S; Hieke K; Hutchinson J; Mimaud V; Berdeaux G
    Pharmacoeconomics; 2006; 24(2):193-205. PubMed ID: 16460138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the European and American guidelines on hypertension prevalence, treatment, and cardiometabolic goals.
    Gijón-Conde T; Sánchez-Martínez M; Graciani A; Cruz JJ; López-García E; Ortolá R; Rodríguez-Artalejo F; Banegas JR
    J Hypertens; 2019 Jul; 37(7):1393-1400. PubMed ID: 31145710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.
    Ryan J; Zoellner Y; Gradl B; Palache B; Medema J
    Vaccine; 2006 Nov; 24(47-48):6812-22. PubMed ID: 17034909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Direct and indirect costs associated with respiratory allergic diseases in Italy. A probabilistic cost of illness study].
    Marcellusi A; Viti R; Incorvaia C; Mennini FS
    Recenti Prog Med; 2015 Oct; 106(10):517-27. PubMed ID: 26442978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model.
    Scholze J; Alegria E; Ferri C; Langham S; Stevens W; Jeffries D; Uhl-Hochgraeber K
    BMC Public Health; 2010 Sep; 10():529. PubMed ID: 20813031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of adherence in the management of hypertension.
    Martell Claros N
    Hipertens Riesgo Vasc; 2023; 40(1):34-39. PubMed ID: 36057521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication Adherence and Blood Pressure Control Among Hypertensive Patients With Coexisting Long-Term Conditions in Primary Care Settings: A Cross-Sectional Analysis.
    Li YT; Wang HHX; Liu KQL; Lee GKY; Chan WM; Griffiths SM; Chen RL
    Medicine (Baltimore); 2016 May; 95(20):e3572. PubMed ID: 27196458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.
    Cruess AF; Zlateva G; Xu X; Soubrane G; Pauleikhoff D; Lotery A; Mones J; Buggage R; Schaefer C; Knight T; Goss TF
    Pharmacoeconomics; 2008; 26(1):57-73. PubMed ID: 18088159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
    Orofino J; Soto J; Casado MA; Oyagüez I
    Appl Health Econ Health Policy; 2010; 8(5):301-15. PubMed ID: 20804223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of enhancing adherence to therapy with blood pressure-lowering drugs in the setting of primary cardiovascular prevention.
    Scotti L; Baio G; Merlino L; Cesana G; Mancia G; Corrao G
    Value Health; 2013; 16(2):318-24. PubMed ID: 23538184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.